The water infrastructure specialist couldn't live up to the stock's high valuation.

Xylem's (XYL) second-quarter 2024 organic revenues increase 9% year over year, driven by the impressive performances of its segments.

Xylem Inc. (NYSE:XYL ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Andrea van der Berg - Vice President, Investor Relations Matthew Pine - Chief Executive Officer Bill Grogan - Chief Financial Officer Conference Call Participants Deane Dray - RBC Capital Markets Mike Halloran - Robert W. Baird Scott Davis - Melius Research Nathan Jones - Stifel Nicolaus Joseph Giordano - TD Cowen Andrew Kaplowitz - Citigroup Bryan Blair - Oppenheimer Operator Good day, everyone, and welcome to the Xylem's Second Quarter 2024 Results Conference Call.

Although the revenue and EPS for Xylem (XYL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Xylem (XYL) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.98 per share a year ago.

Get a deeper insight into the potential performance of Xylem (XYL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Xylem's (XYL) second-quarter 2024 results are likely to gain from strength across its smart metering and other applications end markets despite weakness in the building solutions end market.

Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WASHINGTON--(BUSINESS WIRE)-- #LetsSolveWater--Xylem has announced the grand prize winners of its 2024 Xylem Global Student Innovation Challenge.

One of the best ways to multiply your wealth every summer is by picking up some of the top hurricane stocks to buy. With Hurricane Beryl, we were again reminded of how powerful and destructive hurricanes can be.

CHICAGO--(BUSINESS WIRE)-- #3Dmodeling--ImmersiveTouch Inc., a leading digital surgery company, announced today that its groundbreaking augmented reality (AR) technology platform, ImmersiveAR, has received 510(k) clearance for clinical use in the operating room by the U.S. Food and Drug Administration (FDA). The Chicago-based company will commence immediate commercialization of the platform in the United States. ImmersiveAR is a natural extension of ImmersiveTouch's AI-powered suite of virtual surgical plann.

On-going deployment of Federal support across industrial, energy, and agriculture sectors is a strong tailwind for CapEx, notes Dr. Bruce Kahn. He discusses potential catalysts for ESG stocks.